中國再生醫學(08158.HK)擬與金新合作開發醫療產業園
格隆匯 3 月 22日丨中國再生醫學(08158.HK)宣佈,於2021年3月22日,公司與金新控股集團("金新")訂立不具法律約束力的意向備忘錄,內容有關可能於中國共同發展醫療產業園。
金新為於中國發展醫療產業園,已成立常州中再生健康產業發展有限公司("目標公司")。根據意向備忘錄,已擬定(i)公司將有權(但並無責任)投資目標公司的總計合共最多50%股權;及(ii)集團將負責(其中包括)設計建議、品牌打造及客户引入,而金新將負責(其中包括)產業園的土地招標、建設及營運。
據悉,金新為於中國註冊成立的有限公司,主要從事房地產發展,涵蓋保健及接待等多個行業。目標公司為於中國註冊成立的有限責任公司,由金新全資擁有。目標公司的業務範疇包括房地產開發經營、工程建設、健康諮詢服務、住房及非居住房租賃及物業管理。
公吿稱,集團主要從事組織工程及再生醫學產品的研發、生產及銷售,其業務範圍橫跨多個界別,包括組織工程、化粧品、細胞存儲、製備及治療及醫院管理。集團的業務策略為與中國公司合作,以補足集團的資源及優勢,提高公司在中國的服務水平。
董事認為,一旦落實,與金新合作開發醫療產業園將有助集團在中國提高服務水平及拓展渠道,而金新所擁有的房地產資源及行業經驗,將於該合作中戰略補足集團在醫院管理方面的資源及專業知識。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.